The therapeutic potential of small-conductance KCa2 channels in neurodegenerative and psychiatric diseases

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 10, 2013, Pages 1203-1220

  Lam, Jenny ^a   Coleman, Nichole ^a   Garing, April Lourdes A ^a   Wulff, Heike ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

1 EBIO; Afterhyperpolarization; Alcohol dependence and withdrawal; Alzheimer's disease; Apamin; Ataxia; Calcium activated potassium channel; KCa2; Learning and memory; NS13001; NS309; Parkinson's disease; Riluzole; Schizophrenia; SKA 31; Small conductance

Indexed keywords

1 EBIO; AMANTADINE; APAMIN; APOMORPHINE; BENZATROPINE; BROMOCRIPTINE; CARBAMIC ACID DERIVATIVE; DONEPEZIL; ENTACAPONE; GALANTAMINE; GW 542573X; LEVODOPA; MEMANTINE; NS 13001; NS 309; NS 8593; POTASSIUM CHANNEL STIMULATING AGENT; PRAMIPEXOLE; RILUZOLE; RIVASTIGMINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; SKA 31; SMALL CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; SMALL CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL ACTIVATOR; TOLCAPONE; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLPIDEM;

ACTION POTENTIAL; ALCOHOL ABUSE; ALCOHOLISM; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ATAXIA; BEHAVIOR CHANGE; CELL MEMBRANE DEPOLARIZATION; CEREBELLAR ATAXIA; DEGENERATIVE DISEASE; DRUG MECHANISM; DRUG TARGETING; ELECTRIC SHOCK; HIPPOCAMPUS; HUMAN; LEARNING; MEMORY; MENTAL DISEASE; MULTIPLE SCLEROSIS; NERVE CELL EXCITABILITY; NEUROPROTECTION; PARKINSON DISEASE; PROTEIN EXPRESSION; REVIEW; SCHIZOPHRENIA; SEDATION; SPINAL CEREBELLAR ATAXIA; STRUCTURE ACTIVITY RELATION; SYNAPTIC TRANSMISSION;

ANIMALS; HUMANS; MEMBRANE TRANSPORT MODULATORS; MENTAL DISORDERS; NEURODEGENERATIVE DISEASES; SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS;

EID: 84884572391     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.823161     Document Type: Review

References (144)

1. Wei AD, Gutman GA, Aldrich R, et al. International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels. Pharmacol Rev 2005;57:463-72
2. Kohler M, Hirschberg B, Bond CT, et al. Small-conductance, calcium-activated potassium channels from mammalian brain. Science 1996;273:1709-14
3. Xia XM, Fakler B, Rivard A, et al. Mechanism of calcium gating in small-conductance calcium-activated potassium channels. Nature 1998;395:503-7
4. Chen MX, Gorman SA, Benson B, et al. Small and intermediate conductance Ca2+-activated K+ channels confer distinctive patterns of distribution in human tissues and differential cellular localisation in the colon and corpus cavernosum. Naunyn Schmiedebergs Arch Pharmacol 2004;369:602-15
5. Stocker M, Pedarzani P. Differential distribution of three Ca2+-activated K+ channel subunits, SK1, SK2, and SK3, in the adult rat central nervous system. Mol Cell Neurosci 2000;15:476-93
6. Sailer CA, Hu H, Kaufmann WA, et al. Regional differences in distribution and functional expression of small-conductance Ca2+-activated K+ channels in rat brain. J Neurosci 2002;22:9698-707
7. Sailer CA, Kaufmann WA, Marksteiner J, Knaus HG. Comparative immunohistochemical distribution of three small-conductance Ca2+-activated potassium channel subunits, SK1, SK2, and SK3 in mouse brain. Mol Cell Neurosci 2004;26:458-69
8. Bahia PK, Suzuki R, Benton DC, et al. A functional role for small-conductance calcium-activated potassium channels in sensory pathways including nociceptive processes. J Neurosci 2005;25:3489-98
9. Mongan LC, Hill MJ, Chen MX, et al. The distribution of small and intermediate conductance calcium-activated potassium channels in the rat sensory nervous system. Neuroscience 2005;131:161-75
10. Adelman JP, Maylie J, Sah P. Small-conductance Ca2+-activated K+ channels: form and function. Ann Rev Physiol 2012;74:245-69
11. Faber ES, Sah P. Functions of SK channels in central neurons. Clin Exp Pharmacol Physiol 2007;34:1077-83
12. Ren Y, Barnwell LF, Alexander JC, et al. Regulation of surface localization of the small conductance Ca2+-activated potassium channel, SK2, through direct phosphorylation by cAMP-dependent protein kinase. J Biol Chem 2006;281:11769-79
13. Faber ES, Delaney AJ, Power JM, et al. Modulation of SK channel trafficking by beta adrenoceptors enhances excitatory synaptic transmission and plasticity in the amygdala. J Neurosci 2008;28:10803-13
14. Bildl W, Strassmaier T, Thurm H, et al. Protein kinase CK2 is coassembled with small conductance Ca2+-activated K+ channels and regulates channel gating. Neuron 2004;43:847-58
15. Allen D, Fakler B, Maylie J, Adelman JP. Organization and regulation of small conductance Ca2+-activated K+ channel multiprotein complexes. J Neurosci 2007;27:2369-76
16. Wulff H, Kolski-Andreaco A, Sankaranarayanan A, et al. Modulators of small-and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. Curr Med Chem 2007;14:1437-57
17. Wulff H, Zhorov BS. K+ channel modulators for the treatment of neurological disorders and autoimmune diseases. Chem Rev 2008;108:1744-73
18. Pedarzani P, Stocker M. Molecular and cellular basis of small-and intermediate-conductance, calcium-activated potassium channel function in the brain. Cell Mol Life Sci 2008;65:3196-217
19. Lamy C, Goodchild SJ, Weatherall KL, et al. Allosteric block of KCa2 channels by apamin. J Biol Chem 2010;285:27067-77
20. Goodchild SJ, Xu H, Es-Salah-Lamoureux Z, et al. Basis for allosteric open-state stabilization of voltage-gated potassium channels by intracellular cations. J Gen Physiol 2012;140:495-511
21. Castle NA, Strong PN. Identification of two toxins from scorpion (Leiurus quinquestriatus) venom which block distinct classes of calcium-activated potassium channel. FEBS Lett 1986;209:117-21
22. Auguste P, Hugues M, Grave B, et al. Leiurotoxin I (scyllatoxin), a peptide ligand for Ca2+-activated K+ channels. Chemical synthesis, radiolabeling, and receptor characterization. J Biol Chem 1990;265:4753-9
23. Pedarzani P, D'Hoedt D, Doorty KB, et al. Tamapin, a venom peptide from the Indian red scorpion (Mesobuthus tamulus) that targets small conductance Ca2+-activated K+ channels and afterhyperpolarization currents in central neurons. J Biol Chem 2002;277:46101-9
24. Conejo-Garcia A, Campos JM. Bis-quinolinium cyclophanes: highly potent and selective non-peptidic blockers of the apamin-sensitive Ca2+-activated K+ channel. Curr Med Chem 2008;15:1305-15
25. Pedarzani P, Mosbacher J, Rivard A, et al. Control of electrical activity in central neurons by modulating the gating of small conductance Ca2+-activated K+ channels. J Biol Chem 2001;276:9762-9
26. Lappin SC, Dale TJ, Brown JT, et al. Activation of SK channels inhibits epileptiform bursting in hippocampal CA3 neurons. Brain Res 2005;1065:37-46
27. Strobaek D, Teuber L, Jorgensen TD, et al. Activation of human IK and SK Ca2+-activated K+ channels by NS309 (6,7-dichloro-1H-indole-2,3-dione 3-oxime). Biochim Biophys Acta 2004;1665:1-5
28. Sankaranarayanan A, Raman G, Busch C, et al. Naphtho[1,2-d]thiazol-2- ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol 2009;75:281-95
29. Hougaard C, Eriksen BL, Jorgensen S, et al. Selective positive modulation of the SK3 and SK2 subtypes of small conductance Ca2+-activated K+ channels. Br J Pharmacol 2007;151:655-65
30. Kasumu AW, Hougaard C, Rode F, et al Selective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of spinocerebellar ataxia type Chem Biol 2012;19:1340-53
31. Balut CM, Hamilton KL, Devor DC. Trafficking of intermediate (KCa3.1) and small (KCa2.X) conductance, Ca2+-activated K+ channels: a novel target for medicinal chemistry efforts? Chem Med Chem 2012;7:1741-55
32. Hougaard C, Jensen ML, Dale TJ, et al. Selective activation of the SK1 subtype of human small-conductance Ca2+-activated K+ channels by 4-(2-methoxyphenylcarbamoyloxymethyl)-piperidine-1-carboxylic acid tert-butyl ester (GW542573X) is dependent on serine 293 in the S5 segment. Mol Pharmacol 2009;76:569-78
33. Anderson NJ, Slough S, Watson WP. In vivo characterisation of the small-conductance KCa (SK) channel activator 1-ethyl-2-benzimidazolinone (1-EBIO) as a potential anticonvulsant. Eur J Pharmacol 2006;546:48-53
34. Jenkins DP, Strobaek D, Hougaard C, et al. Negative gating modulation by (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine (NS8593) depends on residues in the inner pore vestibule: pharmacological evidence of deep-pore gating of KCa2 channels. Mol Pharmacol 2011;79:899-909
35. Hougaard C, Hammami S, Eriksen BL, et al. Evidence for a common pharmacological interaction site on K (Ca)2 channels providing both selective activation and selective inhibition of the human K(Ca)2.1 subtype. Mol Pharmacol 2012;81:210-19
36. Morgado-Bernal I. Learning and memory consolidation: Linking molecular and behavioral data. Neuroscience 2011;176:12-19
37. Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993;361:31-9
38. Lomo T. The discovery of long-term potentiation. Philos Trans R Soc Lond B Biol Sci 2003;358:617-20
39. Debanne D, Daoudal G, Sourdet V, Russier M. Brain plasticity and ion channels. J Physiol Paris 2003;97:403-14
40. Yamin G. NMDA receptor-dependent signaling pathways that underlie amyloid beta-protein disruption of LTP in the hippocampus. J Neurosci Res 2009;87:1729-36
41. Lin MT, Lujan R, Watanabe M, et al. SK2 channel plasticity contributes to LTP at Schaffer collateral-CA1 synapses. Nat Neurosci 2008;11:170-7
42. Ngo-Anh TJ, Bloodgood BL, Lin M, et al. SK channels and NMDA receptors form a Ca2+-mediated feedback loop in dendritic spines. Nat Neurosci 2005;8:642-9
43. Allen D, Nakayama S, Kuroiwa M, et al. SK2 channels are neuroprotective for ischemia-induced neuronal cell death. J Cereb Blood Flow Metab 2011;31:2302-12
44. Hammond RS, Bond CT, Strassmaier T, et al. Small-conductance Ca2+-activated K+ channel type 2 (SK2) modulates hippocampal learning, memory, and synaptic plasticity. J Neurosci 2006;26:1844-53
45. Zhang L, Krnjevic K. Apamin depresses selectively the after-hyperpolarization of cat spinal motoneurons. Neurosci Lett 1987;74:58-62
46. Bourque CW, Brown DA. Apamin and D-tubocurarine block the afterhyperpolarization of rat supraoptic neurosecretory neurons. Neurosci Lett 1987;82:185-90
47. Schwindt PC, Spain WJ, Foehring RC, et al. Slow conductances in neurons from cat sensorimotor cortex in vitro and their role in slow excitability changes. J Neurophysiol 1988;59:450-67
48. Avanzini G, de Curtis M, Panzica F, Spreafico R. Intrinsic properties of nucleus reticularis thalami neurones of the rat studied in vitro. J Physiol 1989;416:111-22
49. Sah P, McLachlan EM. Potassium currents contributing to action potential repolarization and the afterhyperpolarization in rat vagal motoneurons. J Neurophysiol 1992;68:1834-41
50. Shepard PD, Stump D. Nifedipine blocks apamin-induced bursting activity in nigral dopamine-containing neurons. Brain Res 1999;817:104-9
51. Zhang L, McBain CJ. Potassium conductances underlying repolarization and after-hyperpolarization in rat CA1 hippocampal interneurons. J Physiol 1995;488:661-72
52. Savic N, Pedarzani P, Sciancalepore M. Medium afterhyperpolarization and firing pattern modulation in interneurons of stratum radiatum in the CA3 hippocampal region. J Neurophysiol 2001;85:1986-97
53. Williams S, Serafin M, Muhlethaler M, Bernheim L. Distinct contributions of high-and low-voltage-activated calcium currents to afterhyperpolarizations in cholinergic nucleus basalis neurons of the guinea pig. J Neurosci 1997;17:7307-15
54. Goldberg JA, Wilson CJ. Control of spontaneous firing patterns by the selective coupling of calcium currents to calcium-activated potassium currents in striatal cholinergic interneurons. J Neurosci 2005;25:10230-8
55. Maher BJ, Westbrook GL. SK channel regulation of dendritic excitability and dendrodendritic inhibition in the olfactory bulb. J Neurophysiol 2005;94:3743-50
56. Teshima K, Kim SH, Allen CN. Characterization of an apamin-sensitive potassium current in suprachiasmatic nucleus neurons. Neuroscience 2003;12:65-73
57. Madison DV, Nicoll RA. Noradrenaline blocks accommodation of pyramidal cell discharge in the hippocampus. Nature 1982;299:636-8
58. McEchron MD, Disterhoft JF. Hippocampal encoding of non-spatial trace conditioning. Hippocampus 1999;9:385-96
59. Christian KM, Thompson RF. Neural substrates of eyeblink conditioning: acquisition and retention. Learn Mem 2003;10:427-55
60. Disterhoft JF, Oh MM. Learning, aging and intrinsic neuronal plasticity. Trends Neurosci 2006;29:587-99
61. Pedarzani P, McCutcheon JE, Rogge G, et al. Specific enhancement of SK channel activity selectively potentiates the afterhyperpolarizing current i(AHP) and modulates the firing properties of hippocampal pyramidal neurons. J Biol Chem 2005;280:41404-11
62. McKay BM, Oh MM, Disterhoft JF. Learning increases intrinsic excitability of hippocampal interneurons. J Neurosci 2013;33:5499-506
63. Mourre C, Fournier C, Soumireu-Mourat B. Apamin, a blocker of the calcium-activated potassium channel, induces neurodegeneration of Purkinje cells exclusively. Brain Res 1997;778:405-8
64. Mpari B, Sreng L, Manrique C, Mourre C. KCa2 channels transiently downregulated during spatial learning and memory in rats. Hippocampus 2010;20:352-63
65. Deschaux O, Bizot JC, Goyffon M. Apamin improves learning in an object recognition task in rats. Neurosci Lett 1997;222:159-62
66. Stackman RW, Hammond RS, Linardatos E, et al. Small conductance Ca2+-activated K+ channels modulate synaptic plasticity and memory encoding. J Neurosci 2002;22:10163-71
67. Inan SY, Aksu F, Baysal F. The effects of some K+ channel blockers on scopolamine-or electroconvulsive shock-induced amnesia in mice. Eur J Pharmacol 2000;407:159-64
68. Messier C, Mourre C, Bontempi B, et al. Effect of apamin, a toxin that inhibits Ca2+-dependent K+ channels, on learning and memory processes. Brain Res 1991;551:322-6
69. Deschaux O, Bizot JC. Effect of apamin, a selective blocker of Ca2+-activated K+-channel, on habituation and passive avoidance responses in rats. Neurosci Lett 1997;227:57-60
70. Baker KD, Edwards TM, Rickard NS. Blocking SK channels impairs long-term memory formation in young chicks. Behav Brain Res 2011;216:458-62
71. Blank T, Nijholt I, Kye MJ, et al. Smallconductance, Ca2+-activated K+ channel SK3 generates age-related memory and LTP deficits. Nat Neurosci 2003;6:911-12
72. McKay BM, Oh MM, Galvez R, et al. Increasing SK2 channel activity impairs associative learning. J Neurophysiol 2012;108:863-70
73. Vick KA, Guidi M, Stackman RW Jr. In vivo pharmacological manipulation of small conductance Ca2+-activated K+ channels influences motor behavior, object memory and fear conditioning. Neuropharmacology 2010;58:650-9
74. Hains AB, Arnsten AF. Molecular mechanisms of stress-induced prefrontal cortical impairment: implications for mental illness. Learn Mem 2008;15:551-64
75. Faber ES, Delaney AJ, Sah P. SK channels regulate excitatory synaptic transmission and plasticity in the lateral amygdala. Nat Neurosci 2005;8:635-41
76. Atchley D, Hankosky ER, Gasparotto K, Rosenkranz JA. Pharmacological enhancement of calcium-activated potassium channel function reduces the effects of repeated stress on fear memory. Behav Brain Res 2012;232:37-43
77. Wynn P. AHCPR releases last guidelines: diagnosing early Alzheimer's. Manag Care 1997;6:18
78. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association Workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-9
79. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-22
80. Parent A, Linden DJ, Sisodia SS, Borchelt DR Synaptic transmission and hippocampal long-term potentiation in transgenic mice expressing FAD-linked presenilin Neurobiol Dis 1999;6:56-62
81. Chakroborty S, Goussakov I, Miller MB, Stutzmann GE. Deviant ryanodine receptor-mediated calcium release resets synaptic homeostasis in presymptomatic 3xTg-AD mice. J Neurosci 2009;29:9458-70
82. Goussakov I, Miller MB, Stutzmann GE. NMDA-mediated Ca2+ influx drives aberrant ryanodine receptor activation in dendrites of young Alzheimer's disease mice. J Neurosci 2010;30:12128-37
83. Chakroborty S, Kim J, Schneider C, et al. Early presynaptic and postsynaptic calcium signaling abnormalities mask underlying synaptic depression in presymptomatic Alzheimer's disease mice. J Neurosci 2012;32:8341-53
84. Dolga AM, Terpolilli N, Kepura F, et al. KCa2 channels activation prevents [Ca2+] i deregulation and reduces neuronal death following glutamate toxicity and cerebral ischemia. Cell Death Dis 2011;2:e147
85. Murthy SR, Teodorescu G, Nijholt IM, et al. Identification and characterization of a novel, shorter isoform of the small conductance Ca2+-activated K+ channel SK2. J Neurochem 2008;106:2312-21
86. Dolga AM, Granic I, Blank T, et al. TNF-alpha-mediates neuroprotection against glutamate-induced excitotoxicity via NF-kappaB-dependent up-regulation of KCa2.2 channels. J Neurochem 2008;107:1158-67
87. Geurts JJ, Wolswijk G, Bo L, et al. Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis. Brain 2003;126:1755-66
88. Killestein J, Kalkers NF, Polman CH. Glutamate inhibition in MS: the neuroprotective properties of riluzole. J Neurol Sci 2005;233:113-15
89. Grunnet M, Jespersen T, Angelo K, et al. Pharmacological modulation of SK3 channels. Neuropharmacology 2001;40:879-87
90. Ikonen S, Riekkinen P Jr. Effects of apamin on memory processing of hippocampal-lesioned mice. Eur J Pharmacol 1999;382:151-6
91. Marras C, Lang A, Krahn M, et al. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. Mov Disord 2004;19:22-8
92. Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998;339:1044-53
93. Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G. What predicts mortality in Parkinson disease?: a prospective population-based long-term study. Neurology 2010;75:1270-6
94. Sarpal D, Koenig JI, Adelman JP, et al. Regional distribution of SK3 mRNA-containing neurons in the adult and adolescent rat ventral midbrain and their relationship to dopamine-containing cells. Synapse 2004;53:104-13
95. Wolfart J, Neuhoff H, Franz O, Roeper J. Differential expression of the small-conductance, calcium-activated potassium channel SK3 is critical for pacemaker control in dopaminergic midbrain neurons. J Neurosci 2001;21:3443-56
96. Waroux O, Massotte L, Alleva L, et al. SK channels control the firing pattern of midbrain dopaminergic neurons in vivo. Eur J Neurosci 2005;22:3111-21
97. Herrik KF, Redrobe JP, Holst D, et al. CyPPA, a positive SK3/SK2 modulator, reduces activity of dopaminergic neurons, inhibits dopamine release, and counteracts hyperdopaminergic behaviors induced by methylphenidate. Front Pharmacol 2012;3:11
98. Aumann TD, Gantois I, Egan K, et al. SK channel function regulates the dopamine phenotype of neurons in the substantia nigra pars compacta. Exp Neurol 2008;213:419-30
99. Benitez BA, Belalcazar HM, Anastasia A, et al. Functional reduction of SK3-mediated currents precedes AMPA-receptor-mediated excitotoxicity in dopaminergic neurons. Neuropharmacology 2011;60:1176-86
100. Durr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol 2010;9:885-94
101. Clauss R, Sathekge M, Nel W. Transient improvement of spinocerebellar ataxia with zolpidem. N Engl J Med 2004;351:511-12
102. Zesiewicz TA, Greenstein PE, Sullivan KL, et al A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type Neurology 2012;78:545-50
103. Aizenman CD, Linden DJ. Regulation of the rebound depolarization and spontaneous firing patterns of deep nuclear neurons in slices of rat cerebellum. J Neurophysiol 1999;82:1697-09
104. Shakkottai VG, Chou CH, Oddo S, et al. Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia. J Clin Invest 2004;113:582-90
105. Shakkottai VG, do Carmo Costa M, Dell'Orco JM, et al Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type J Neurosci 2011;31:13002-14
106. Walter JT, Alvina K, Womack MD, et al. Decreases in the precision of Purkinje cell pacemaking cause cerebellar dysfunction in ataxia. Nat Neurosci 2006;9:389-97
107. Gao Z, Todorov B, Barrett CF, et al. Cerebellar ataxia by enhanced Cav2.1 currents is alleviated by Ca2+-dependent K+-channel activators in Cacna1a(S218L) mutant mice. J Neurosci 2012;32:15533-46
108. Alvina K, Khodakhah K. KCa channels as therapeutic targets in episodic ataxia type-2. J Neurosci 2010;30:7249-57
109. Ristori G, Romano S, Visconti A, et al. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology 2010;74:839-45
110. Doble A. The pharmacology and mechanism of action of riluzole. Neurology 1996;47:S233-41
111. Murray CJ, Lopez AD. Evidence-based health policy-lessons from the global burden of disease study. Science 1996;274:740-3
112. Kirkpatrick B, Amador XF, Flaum M, et al. The deficit syndrome in the DSM-IV field trial. I. Alcohol and other drug abuse. Schizophrenia Res 1996;20:69-77
113. McGrath J, Saha S, Chant D, Welham J. Schizophrenia. A concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008;30:67-76
114. Strauss JS, Carpenter WT Jr, Bartko JJ. The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophrenia Bull 1974;11:61-9
115. American Psychiatry Association. Diagnostic and statistical manual of mental disorders. 4th edition. Text Revision American Psychiatry Association; 2000
116. Goldman-Rakic PS, Castner SA, Svensson TH, et al. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology 2004;174:3-16
117. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-8
118. Hashimoto T, Volk DW, Eggan SM, et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 2003;23:6315-26
119. Volk DW, Pierri JN, Fritschy JM, et al. Reciprocal alterations in pre-and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb Cortex 2002;12:1063-70
120. Volk D, Austin M, Pierri J, et al. GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons. Am J Psychiatry 2001;158:256-65
121. Avila MT, Sherr JD, Hong E, et al. Effects of nicotine on leading saccades during smooth pursuit eye movements in smokers and nonsmokers with schizophrenia. Neuropsychopharmacology 2003;28:2184-91
122. Olincy A, Harris JG, Johnson LL, et al. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006;63:630-8
123. Sherr JD, Myers C, Avila MT, et al. The effects of nicotine on specific eye tracking measures in schizophrenia. Biol Psychiatry 2002;52:721-8
124. Farde L. Brain imaging of schizophrenia-the dopamine hypothesis. Schizophr Res 1997;28:157-62
125. Meyer-Lindenberg A, Miletich RS, Kohn PD, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 2002;5:267-71
126. Heckers S. Neuroimaging studies of the hippocampus in schizophrenia. Hippocampus 2001;11:520-8
127. Ping HX, Shepard PD. Apamin-sensitive Ca2+-activated K+ channels regulate pacemaker activity in nigral dopamine neurons. Neuroreport 1996;7:809-14
128. Shepard PD, Bunney BS. Effects of apamin on the discharge properties of putative dopamine-containing neurons in vitro. Brain Res 1988;463:380-4
129. Steketee JD, Kalivas PW. Effect of microinjections of apamin into the A10 dopamine region of rats: a behavioral and neurochemical analysis. J Pharmacol Exp Ther 1990;254:711-19
130. Stocker M, Krause M, Pedarzani P. An apamin-sensitive Ca2+-activated K+ current in hippocampal pyramidal neurons. Proc Natl Acad Sci USA 1999;96:4662-7
131. Morse RM, Flavin DK. The definition of alcoholism. The joint committee of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to study the definition and criteria for the diagnosis of alcoholism. JAMA 1992;268:1012-14
132. Zhang Y, Guo X, Saitz R, et al. Secular trends in alcohol consumption over 50 years: the Framingham study. Am J Med 2008;121:695-01
133. Spanagel R. Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol Rev 2009;89:649-05
134. Harwood HJ, Fountain D, Fountain G. Economic cost of alcohol and drug abuse in the United States, 1992: a report. Addiction 1999;94:631-5
135. Zaridze D, Brennan P, Boreham J, et al. Alcohol and cause-specific mortality in Russia: a retrospective case-control study of 48,557 adult deaths. Lancet 2009;373:2201-14
136. Thun MJ, Peto R, Lopez AD, et al. Alcohol consumption and mortality among middle-aged and elderly U.S. Adults. N Engl J Med 1997;337:1705-14
137. Moss HB, Chen CM, Yi HY. Prospective follow-up of empirically derived alcohol dependence subtypes in wave 2 of the national epidemiologic survey on alcohol and related conditions (NESARC): recovery status, alcohol use disorders and diagnostic criteria, alcohol consumption behavior, health status, and treatment seeking. Alcohol Clin Exp Res 2010;34:1073-83
138. Weiss RD, O'Malley SS, Hosking JD, et al. Do patients with alcohol dependence respond to placebo? Results from the combine study. J Stud Alcohol Drugs 2008;69:878-84
139. Finney JW, Hahn AC, Moos RH. The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects. Addiction 1996;91:1773-96
140. Hopf FW, Bowers MS, Chang SJ, et al. Reduced nucleus accumbens SK channel activity enhances alcohol seeking during abstinence. Neuron 2010;65:682-94
141. Mulholland PJ, Becker HC, Woodward JJ, Chandler LJ. Small conductance calcium-activated potassium type 2 channels regulate alcohol-associated plasticity of glutamatergic synapses. Biol Psychiatry 2011;69:625-32
142. Hopf FW, Simms JA, Chang SJ, et al. Chlorzoxazone, an SK-type potassium channel activator used in humans, reduces excessive alcohol intake in rats. Biol Psychiatry 2011;69:618-24
143. Etherington JM. Emergency management of acute alcohol problems. Part 2: alcohol-related seizures, delirium tremens, and toxic alcohol ingestion. Can Fam Physician 1996;42:2423-31
144. Becker HC, Lopez MF. Increased ethanol drinking after repeated chronic ethanol exposure and withdrawal experience in C57BL/6 mice. Alcohol Clin Exp Res 2004;28:1829-38